Stocktwits on MSN
REPL ignites on doctor fury against FDA’s melanoma drug snub — health sec steps back
FDA refused to approve Replimune’s melanoma drug RP1 for the second time earlier this month citing insufficient data to ...
At a Senate hearing, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Wednesday that he "had nothing to ...
Replimune (REPL) stock plunged 19% after FDA issued second rejection of RP1 melanoma immunotherapy, citing inadequate trial design and controls.
Replimune Group, Inc. stock drops after a second FDA rejection for RP1 melanoma; cash runway <12 months. Click for more on ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Stocktwits on MSN
REPL, HOTH, ONCO stocks hit 52-week lows: What's driving the selloff in these biotech plays?
REPL came under pressure after the FDA issued a second Complete Response Letter for RP1 with nivolumab in anti-PD-1-failed melanoma. ・HOTH declined after a $2 million stock offering, along with ...
An online coding platform called Repl.it is picking up popularity among kids and teenagers, who are using the platform to learn to code and to build apps online. Kids enjoy using Repl.it because they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results